esuberaprost
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT01966302)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
EP300 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC#CC[C@H](C)[C@H](O)/C=C/[C@@H]1[C@H]2c3cccc(CCCC(=O)O)c3O[C@H]2C[C@H]1O- Mol. weight
- 398.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3137314 ↗
Also known as
- bps-314d
- bps-314d
- bps-314d-mr
- esuberaprost
- esuberaprost
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01966302 | Phase 2 | Nov 1, 2013 | Los Angeles Biomedical Research Institute, Lung Biotechnology PBC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Los Angeles Biomedical Research Institute | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Lung Biotechnology PBC | For profit | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1